Does progression from actinic keratosis and Bowen's disease end with treatment: Diclofenac 3% gel, an old drug in a new environment?

M. J. Patel, E. Stockfleth

Research output: Contribution to journalArticlepeer-review

Abstract

Progression from actinic keratosis (AK) and Bowen's disease (BD) to invasive disease involves a complex cascade of events. The preparation of diclofenac 3% gel (Solaraze™; Shire Pharmaceuticals) has been shown to be efficacious and well tolerated in AK. The inhibition of the COX enzymes results in a decrease in downstream by-products of arachidonic acid metabolism. These metabolites have been shown to play a pivotal role in promoting epithelial tumour growth. Given its mechanism of action, we hypothosize that diclofenac 3% gel may have potential to halt the progression of actinic keratoses (AKs) in the setting of field cancerisation and BD. We report a series of five patients with BD, all treated with diclofenac 3% gel with clinical and histological clearance.

Original languageEnglish (US)
Pages (from-to)53-56
Number of pages4
JournalBritish Journal of Dermatology
Volume156
Issue numberSUPPL. 3
DOIs
StatePublished - May 1 2007
Externally publishedYes

Keywords

  • Actinic keratosis
  • Bowen's disease
  • Diclofenac 3% gel

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Does progression from actinic keratosis and Bowen's disease end with treatment: Diclofenac 3% gel, an old drug in a new environment?'. Together they form a unique fingerprint.

Cite this